Welcome
Support Centre
09 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Periodontal therapy in diabetic subjects
ISRCTN ISRCTN11742127
ClinicalTrials.gov identifier
Public title Periodontal therapy in diabetic subjects
Scientific title Efficacy of mechanical scaling and root planning and adjunctive chemotherapy (doxycycline hyclate 20 mg) on systemic health improvement in diabetics
Acronym N/A
Serial number at source 005
Study hypothesis To evaluate the effectiveness of scaling and root planning (SRP) and adjunctive chemotherapy (doxycycline hyclate 20 mg) on gingival health, specific cytokines and glycaemic control within diabetic subjects.
Ethics approval Research Ethics Committee, Sultan Bin Abdulaziz Humanitarian City, Riyadh, Saudi Arabia
Study design A double-masked, randomised, placebo-controlled, multi-centre trial.
Countries of recruitment Saudi Arabia
Disease/condition/study domain Periodontal disease and diabetes mellitus
Participants - inclusion criteria 1. Both males and females, age range 18-65 years old
2. Diabetes, identified as type 1 or 2
3. Have had diabetes for at least 1 year
4. Diabetes is under control by oral hypoglycemic agent or insulin or both
5. Have been on the same type and dose of diabetic medication for the past 6 months
6. Good physical condition with no serious medical conditions or transmittable disease i.e. malignant disease, active hepatitis, free from any cardiac condition that needs antibiotic prophylaxis prior to teeth scaling and root planning
7. Have minimum of 18 remaining natural and non-capped teeth
8. Have minimum of 6 sites in minimum of 2 different quadrants with probing pocket depth (PPD) >=5 mm but <=8 mm
9. Have not had treatment with SRP within 6 months prior to baseline visit
10. Visible supragingival calculus in minimum of 4 teeth in 2 different quadrants
11. Absence of orthodontic bands and brackets and/or dental appliances that would affect scored indices
Participants - exclusion criteria 1. Use of antibiotics within three months prior to baseline appointment
2. Pregnant or nursing female subjects
Anticipated start date 01/04/2006
Anticipated end date 01/04/2007
Status of trial Completed
Patient information material
Target number of participants 500
Interventions The selected subjects were divided into four groups:

1. One session of SRP at baseline visit only, and placebo tablets 20 mg twice/day starting at baseline visit and continuing for 3 months only
2. One session of SRP at baseline visit only, and doxycycline hyclate (oral, 20 mg twice/day) starting at baseline visit and continuing for 3 months only
3. Two sessions of SRP, first at baseline visit and the second at 6-month visit, and placebo tablets 20 mg twice/day at baseline visit and 6-month visit continuing for 3 months from each visit
4. Two sessions of SRP, first at baseline visit and the second at 6-month visit, and doxycycline hyclate 20 mg twice/day at baseline visit and 6-month visit continuing for 3 months from each visit
Primary outcome measure(s) 1. Effectiveness of SRP and adjunctive chemotherapy (doxycycline hyclate 20 mg) on gingival health. The following were assessed at baseline, 3, 6, 9 and 12 months:
1.1. Probing Pocket Depth (PPD)
1.2. Clinical attachment level (CAL)
1.3. Modified gingival index (MGI)
1.4. Plaque index (PI)
1.5. Bleeding on probing (BOP)

2. Effectiveness of SRP and adjunctive chemotherapy (doxycycline hyclate 20 mg) on specific cytokines and glycaemic control in diabetic subjects. Venous blood samples were obtained for laboratory analysis of cytokines (Tumuor Necrosis Factor alpha [TNF-a], Interleukine-1 alpha [IL-1 a]) and to evaluate glycated haemoglobin (HbA1c) for all subjects at baseline, 3, 6, 9 and 12 months.
Secondary outcome measure(s) No secondary outcome measures
Sources of funding King Abdulaziz City for Science and Technology, General Directorate of Research Grants Programmes (Saudi Arabia)
Trial website
Publications
Contact name Dr  Sultan  Al Mubarak
  Address King Faisal Specialist Hospital and Research Centre
PO Box 64399
  City/town Riyadh
  Zip/Postcode 11536
  Country Saudi Arabia
  Tel +966 504180209
  Email salmubarak@kfshrc.edu.sa
Sponsor King Abdulaziz City for Science and Technology (Saudi Arabia)
  Address PO Box 6068
11442
  City/town Riyadh
  Zip/Postcode 11536
  Country Saudi Arabia
  Tel +966 5620000 Ex 5019
  Email aasirvatham@humanitariancity.org.sa
  Sponsor website: http://www.kacst.edu.sa/eng/
Date applied 12/06/2008
Last edited 25/06/2008
Date ISRCTN assigned 25/06/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central